Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Guanze Medical Information Industry (Holding) Co's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 90.51%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
HKSE:02427's 3-Year ROIIC % is ranked better than 80.69% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.385
vs HKSE:02427: 90.51
Guanze Medical Information Industry (Holding) Co (HKSE:02427) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Guanze Medical Information Industry (Holding) Co 3-Year ROIIC % Related Terms
Guanze Medical Information Industry (Holding) Co 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guanze Medical Information Industry (Holding) Co 3-Year ROIIC % Chart
Guanze Medical Information Industry (Holding) Co Annual Data
HKSE:02427 vs TMO, DHR, IDXX: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Guanze Medical Information Industry (Holding) Co's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guanze Medical Information Industry (Holding) Co 3-Year ROIIC % vs Medical Diagnostics & Research Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Guanze Medical Information Industry (Holding) Co (HKSE:02427) has a 3-Year ROIIC % of 90.51 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Guanze Medical Information Industry (Holding) Co and its competitors. According to the industry distribution chart, Guanze Medical Information Industry (Holding) Co ranks #39 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 19.3%.
Is Guanze Medical Information Industry (Holding) Co's 3-Year ROIIC % too high?
Guanze Medical Information Industry (Holding) Co's current 3-Year ROIIC % is 90.51. The Medical Diagnostics & Research industry median 3-Year ROIIC % is 0.39. Guanze Medical Information Industry (Holding) Co's value of 90.51 is 23409.1% above this industry median. Based on the distribution chart, Guanze Medical Information Industry (Holding) Co ranks #39 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Guanze Medical Information Industry (Holding) Co has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guanze Medical Information Industry (Holding) Co's 3-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Guanze Medical Information Industry (Holding) Co ranks #39 out of 202 companies for 3-Year ROIIC %. This places Guanze Medical Information Industry (Holding) Co in the top 19% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 0.39. Guanze Medical Information Industry (Holding) Co's value of 90.51 is 23409.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.39, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guanze Medical Information Industry (Holding) Co's current 3-Year ROIIC % of 90.51 is 23409.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Guanze Medical Information Industry (Holding) Co and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guanze Medical Information Industry (Holding) Co's current 3-Year ROIIC % is 90.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guanze Medical Information Industry (Holding) Co stock overvalued right now?
Based on GuruFocus' analysis, Guanze Medical Information Industry (Holding) Co (HKSE:02427) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.27, compared to a current price of HK$2.30 — trading 751.9% above its estimated fair value. The current 3-Year ROIIC % is 90.51 and 23409.1% above the Medical Diagnostics & Research industry median of 0.39. Guanze Medical Information Industry (Holding) Co's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Guanze Medical Information Industry (Holding) Co (HKSE:02427), the current 3-Year ROIIC % is 90.51 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guanze Medical Information Industry (Holding) Co (HKSE:02427) Overvalued in 2026?
Based on GuruFocus' analysis, Guanze Medical Information Industry (Holding) Co stock appears to be overvalued.
The current stock price of HK$2.30 is trading 751.9% above its estimated GF Value™ of HK$0.27.
GuruFocus considers Guanze Medical Information Industry (Holding) Co to be Significantly Overvalued.
Key valuation signals for HKSE:02427:
3-Year ROIIC %: 90.51
GF Value™: HK$0.27 vs. price of HK$2.30 (751.9% above fair value)
Industry Position: 23409.1% above the Medical Diagnostics & Research median (#39 of 202)
No single metric tells the full story. See the HKSE:02427 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guanze Medical Information Industry (Holding) Co Ltd is a medical imaging solutions provider, principally engaged in providing medical imaging film products and medical imaging cloud services in Shandong Province. The company generates the majority of its revenue from the PRC.
52GF Score
Get the complete analysis for HKSE:02427
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02427 has been successfully added to your 
